These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19575773)

  • 41. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease.
    Ahuja S; Bivalacqua TJ; Case J; Vincent M; Sikka SC; Hellstrom WJ
    J Androl; 1999; 20(4):444-8. PubMed ID: 10452584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Iontophoresis in the conservative treatment of Peyronie's disease: preliminary experience].
    Treffiletti S; Annoscia S; Montefiore F; Boccafoschi C
    Arch Ital Urol Androl; 1997 Dec; 69(5):323-7. PubMed ID: 9477619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Peyronie's disease: treatment with interferon and laser].
    Candebat Montero LH; Miranda Reyes PL; Díaz García F; González Ferro I; Barbosa Ramos F; Codorniu Furet J
    Arch Esp Urol; 2008 Apr; 61(3):413-23. PubMed ID: 18581679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intralesional Interferon-α2b Improves Penile Curvature in Peyronie's Disease.
    Milam DF
    J Urol; 2015 Dec; 194(6):1533. PubMed ID: 26386274
    [No Abstract]   [Full Text] [Related]  

  • 45. Intraplaque verapamil injection for treatment of Peyronie's disease.
    Lasser A; Vandenberg TL; Vincent MJ; Hellstrom WJ
    J La State Med Soc; 1998 Sep; 150(9):431-4. PubMed ID: 9785755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: a prospective, randomised controlled study.
    Favilla V; Russo GI; Privitera S; Castelli T; Madonia M; La Vignera S; Condorelli R; Calogero AE; Farina FP; Cimino S; Morgia G
    Andrologia; 2014 Oct; 46(8):936-42. PubMed ID: 24124921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Local interferon-alpha2b is not an effective treatment in early-stage Peyronie's disease.
    Lue TF
    J Urol; 1998 May; 159(5):1777-8. PubMed ID: 9554410
    [No Abstract]   [Full Text] [Related]  

  • 48. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study.
    Jordan GH
    J Sex Med; 2008 Jan; 5(1):180-7. PubMed ID: 18173766
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [La Peyronie disease, erectile dysfunction, kidney tumors]].
    Beley S
    Prog Urol; 2008 Feb; 18(1 Suppl FMC):F32-4. PubMed ID: 18773852
    [No Abstract]   [Full Text] [Related]  

  • 50. Therapeutic advances in the treatment of Peyronie's disease.
    Yafi FA; Pinsky MR; Sangkum P; Hellstrom WJ
    Andrology; 2015 Jul; 3(4):650-60. PubMed ID: 26097120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.
    Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D
    BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome.
    Chung E; Garcia F; Young LD; Solomon M; Brock GB
    J Urol; 2013 Jan; 189(1):380-4. PubMed ID: 23174244
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options.
    Gur S; Limin M; Hellstrom WJ
    Expert Opin Pharmacother; 2011 Apr; 12(6):931-44. PubMed ID: 21405946
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Review of current nonsurgical management of Peyronie's disease.
    Levine LA
    Int J Impot Res; 2003 Oct; 15 Suppl 5():S113-20. PubMed ID: 14551587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in the medical therapy of Peyronie's disease: a brief review.
    Levine LA
    Int J Impot Res; 1998 Jun; 10(2):123-4. PubMed ID: 9647950
    [No Abstract]   [Full Text] [Related]  

  • 56. 'Off-label' drug use in sexual medicine treatment.
    Fallon B
    Int J Impot Res; 2008; 20(2):127-34. PubMed ID: 17851582
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transdermal and topical pharmacotherapy for male sexual dysfunction.
    Ohebshalom M; Mulhall JP
    Expert Opin Drug Deliv; 2005 Jan; 2(1):115-20. PubMed ID: 16296739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the protective effects of papaverine, lidocaine and verapamil on the sperm quality of the testis after induced torsion-detorsion in rats.
    Shirazi M; Noorafshan A; Karbalay-Doust S; Ardeshiri M; Afrasiabi MA; Monabati A
    Scand J Urol Nephrol; 2010 Apr; 44(3):133-7. PubMed ID: 20166843
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease.
    Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Giurioli A; Jannini EA; Vespasiani G
    J Urol; 2004 Apr; 171(4):1605-8. PubMed ID: 15017231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Correction of acquired penile curvatures].
    Mantovani F; Patelli E; Colombo F
    Arch Ital Urol Androl; 1998 Dec; 70(5):223-6. PubMed ID: 9882903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.